MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Repetitive Transcranial Magnetic Stimulation Versus Botulinum Injection on Spasticity on Children With Diplegic Cerebral Palsy

Not Applicable
Conditions
Spastic Diplegic Cerebral Palsy
Interventions
Device: Transcranial Magnetic Stimulation
Drug: botulinum toxin A
Other: Rehabilitation Training Protocol
First Posted Date
2024-01-23
Last Posted Date
2024-07-03
Lead Sponsor
MTI University
Target Recruit Count
75
Registration Number
NCT06218316
Locations
🇪🇬

faculty of pysical therapy, MTI university, Cairo, Egypt

Migraine Medication Effects on Urinary Symptoms

Conditions
Bladder Pain Syndrome
Migraine Disorders
Migraine
Overactive Bladder
Overactive Bladder Syndrome
Overactive Detrusor
Interstitial Cystitis
Interventions
First Posted Date
2024-01-19
Last Posted Date
2024-05-16
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
200
Registration Number
NCT06212661
Locations
🇺🇸

Cleveland Clinic, Main Campus, Cleveland, Ohio, United States

Efficacy of Extracorporeal Shock Wave Therapy in Children With Cerebral Palsy

Phase 3
Not yet recruiting
Conditions
Spasticity/Paresis
Cerebral Palsy
Interventions
Device: ESWT
Drug: Botulinum Toxin Type A
Other: Serial Casting
Behavioral: Physical Therapy
Behavioral: Occupational Therapy
First Posted Date
2023-11-13
Last Posted Date
2023-11-18
Lead Sponsor
Kocaeli University
Target Recruit Count
40
Registration Number
NCT06128616

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared with Placebo Injections in Participants Aged 18 Years and Older with Chronic Nerve Pain After Shingles or Nerve Injury

Phase 2
Recruiting
Conditions
Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
Interventions
First Posted Date
2023-10-19
Last Posted Date
2024-12-20
Lead Sponsor
Merz Therapeutics GmbH
Target Recruit Count
120
Registration Number
NCT06091020
Locations
🇧🇬

Merz Investigational Site #3590002, Sofia, Bulgaria

🇧🇬

Merz Investigational Site #3590003, Veliko Turnovo, Bulgaria

🇧🇬

Merz Investigational Site #3590005, Sofia, Bulgaria

and more 28 locations

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Phase 3
Recruiting
Conditions
Episodic Migraine
Interventions
First Posted Date
2023-09-21
Last Posted Date
2024-12-27
Lead Sponsor
Ipsen
Target Recruit Count
714
Registration Number
NCT06047457
Locations
🇺🇸

CCT Research, Phoenix, Arizona, United States

🇺🇸

HonorHealth Neurology, Scottsdale, Arizona, United States

🇫🇷

CHU Nimes - Hôpital Caremeau, Nîmes, France

and more 78 locations

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Phase 3
Recruiting
Conditions
Chronic Migraine
Interventions
First Posted Date
2023-09-21
Last Posted Date
2024-12-27
Lead Sponsor
Ipsen
Target Recruit Count
720
Registration Number
NCT06047444
Locations
🇺🇸

Central Research Associates, Birmingham, Alabama, United States

🇬🇪

ISR-GEO Med Res Clin Healthycore, Tbilisi, Georgia

🇬🇪

"Pineo Medical Ecosystem" LTD, Tbilisi, Georgia

and more 99 locations

Botulinum Toxin for Chronic Neuropathic Pain

Recruiting
Conditions
Neuralgia
Chronic Pain
Interventions
First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
Region Zealand
Target Recruit Count
12
Registration Number
NCT06036043
Locations
🇩🇰

University Hospital of regions Zealand, Køge, Denmark

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

Phase 2
Completed
Conditions
COPD
Interventions
First Posted Date
2023-08-21
Last Posted Date
2024-07-17
Lead Sponsor
RMW Testing
Target Recruit Count
40
Registration Number
NCT06003049
Locations
🇺🇸

Tranquil Clinical Research, Webster, Texas, United States

To Evaluate the Efficacy and Safety of LIZTOX in Subjects With Benign Masseteric Hypertrophy

Phase 3
Recruiting
Conditions
Benign Masseteric Hypertrophy
Interventions
Drug: normal Saline
Drug: Botulinum toxin type A
First Posted Date
2023-07-27
Last Posted Date
2023-07-27
Lead Sponsor
Huons Biopharma
Target Recruit Count
168
Registration Number
NCT05964257
Locations
🇰🇷

Chung-Ang University Hospital, Dongjak, Seoul, Korea, Republic of

Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia

Phase 1
Conditions
Spasmodic Dysphonia
Interventions
First Posted Date
2023-06-07
Last Posted Date
2023-09-18
Lead Sponsor
University of Florida
Target Recruit Count
36
Registration Number
NCT05892770
Locations
🇺🇸

University of Florida- Shands Hospital, Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath